Antony Cousins

Antony Cousins

Auto-generated profile, based on publicly available information

Antony Cousins

Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2017 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CSCarmela De Santo
Carmela De Santo
SBSarah Booth
Sarah Booth
AVAshley Vardon
Ashley Vardon
ACAntony Cousins
Antony Cousins
VTVanessa Tubb
Vanessa Tubb
FMFrancis Mussai
Francis Mussai
Arginine is a semi‐essential amino acid that plays a key role in cell survival and proliferation in normal and malignant cells. BCT‐100, a pegylated (PEG) recombinant human arginase, can deplete arginine and starve malignant cells of the amino acid. Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood, yet for patients with high risk or relapsed disease prognosis remains poor. We show that BCT‐100 is cytotoxic to ALL blasts from patients in vitro by necrosis, and is synergistic in combination with dexamethasone. Against ALL xenografts, BCT‐100 leads to a reduction in ALL engraftment and a prolongation of survival. ALL blasts express the arginine transporter CAT‐1, yet the majority of blasts are arginine auxotrophic due to deficiency in either argininosuccinate synthase (ASS) or ornithine transcarbamylase (OTC). Although endogenous upregulation or retroviral transduced increases in ASS or OTC may promote ALL survival under moderately low arginine conditions, expression of these enzymes cannot prevent BCT‐100 cytotoxicity at arginine depleting doses. RNA‐sequencing of ALL blasts and supporting stromal cells treated with BCT‐100 identifies a number of candidate pathways which are altered in the presence of arginine depletion. Therefore, BCT‐100 provides a new clinically relevant therapeutic approach to target arginine metabolism in ALL.

28 September 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
ASAngela Maria Savino
Angela Maria Savino
SFSara Isabel Fernandes
Sara Isabel Fernandes
OOOrianne Olivares
Orianne Olivares
AZAnna Zemlyansky
Anna Zemlyansky
ACAntony Cousins
Antony Cousins
CHChristina Halsey
Christina Halsey

11 October 2018 in Blood
Verified
Journal Article
Closed access
PDF file
AAAmeera Alsadeq
Ameera Alsadeq
LLLennart Lenk
Lennart Lenk
AVAnila Vadakumchery
Anila Vadakumchery
ACAntony Cousins
Antony Cousins
CVChristian Vokuhl
Christian Vokuhl
HJHassan Jumaa
Hassan Jumaa

15 January 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
LLLennart Lenk
Lennart Lenk
MCMichela Carlet
Michela Carlet
FVFotini Vogiatzi
Fotini Vogiatzi
LSLea Spory
Lea Spory
DWDorothee Winterberg
Dorothee Winterberg
DSDenis Martin Schewe
Denis Martin Schewe
Central nervous system (CNS) involvement remains a challenge in the diagnosis and treatment of acute lymphoblastic leukemia (ALL). In this study, we identify CD79a (also known as Igα), a signaling component of the preB cell receptor (preBCR), to be associated with CNS-infiltration and –relapse in B-cell precursor (BCP)-ALL patients. Furthermore, we show that downregulation of CD79a hampers the engraftment of leukemia cells in different murine xenograft models, particularly in the CNS.

24 January 2015 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
ACAntony F. Cousins
Antony F. Cousins
JSJoy E. Sinclair
Joy E. Sinclair
MAMichael J Alcorn
Michael J Alcorn
RGRachel H.A. Green
Rachel H.A. Green
KDKenny W. Douglas
Kenny W. Douglas

11 November 2021 in Blood
Verified
Journal Article
Closed access
PDF file
CZCostanza Zanetti
Costanza Zanetti
RKRahul Kumar
Rahul Kumar
JEJoscha Ender
Joscha Ender
PGParimala S. Godavarthy
Parimala S. Godavarthy
MHMark Hartmann
Mark Hartmann
DKDaniela S. Krause
Daniela S. Krause
B-cell acute lymphoblastic leukemia (B-ALL) occurs most commonly in children, whereas chronic myeloid leukemia is more frequent in adults. The myeloid bias of hematopoiesis in elderly individuals has been considered causative, but the age of the bone marrow microenvironment (BMM) may be contributory. Using various murine models of B-ALL in young vs old mice, we recapitulated B-ALL preponderance in children vs adults. We showed differential effects of young vs old BM macrophages on B-ALL cell function. Molecular profiling using RNA- and ATAC-sequencing revealed pronounced differences in young vs old BMM-derived macrophages and enrichment for gene sets associated with inflammation. In concordance with the role of C-X-C motif chemokine (CXCL) 13 for disease-associated B-cell chemoattraction, we found CXCL13 to be highly expressed in young macrophages on a translational compared with a transcriptional level. Inhibition of CXCL13 in BM macrophages impaired leukemia cell migration and decreased the proliferation of cocultured B-ALL cells, whereas recombinant CXCL13 increased pAKT and B-ALL cell expansion. Pretreatment of B-ALL–initiating cells with CXCL13 accelerated B-ALL progression. Deficiency of Cxcr5, the receptor for CXCL13, on B-ALL–initiating cells prolonged murine survival, whereas high expression of CXCR5 in pediatric B-ALL may predict central nervous system relapse. CXCL13 staining was increased in bone sections from pediatric compared with adult patients with B-ALL. Taken together, our study shows that the age of the BMM and, in particular, BM macrophages influence the leukemia phenotype. The CXCR5-CXCL13 axis may act as prognostic marker and an attractive novel target for the treatment of B-ALL.